Fragment-based design and MD simulations of human papilloma virus-16 E6 protein inhibitors

References

• Allison, D. B., & Maleki, Z. (2016). HPV-related head and neck squamous cell carcinoma: An update and review. Journal of the American Society of Cytopathology, 5(4), 203–215. https://doi.org/10.1016/j.jasc.2015.12.001
   PubMedGoogle Scholar
• Arokiaraj, S. R., Tajuddin, N. B., Muthusamy, K., Jayaraj, J. M., & Alagumuthu, M. (2020). TRAF2 and NCK-interacting kinase inhibitors for colorectal cancer: In vitro and theoretical validations. ACS Combinatorial Science, 22(11), 608–616. https://doi.org/10.1021/acscombsci.0c00027
   PubMed Web of Science ®Google Scholar
• Baleja, J. D., Cherry, J. J., Liu, Z., Gao, H., Nicklaus, M. C., Voigt, J. H., Chen, J. J., & Androphy, E. J. (2006). Identification of inhibitors to papillomavirus type 16 E6 protein based on three-dimensional structures of interacting proteins. Antiviral Research, 72(1), 49–59. https://doi.org/10.1016/j.antiviral.2006.03.014
   PubMed Web of Science ®Google Scholar
• Banerjee, P., Eckert, A. O., Schrey, A. K., & Preissner, R. (2018). ProTox-II – Prediction of toxicity of chemicals. Nucleic Acids Research, 46(W1), W257–W263. https://tox-new.charite.de/protox_II/. https://doi.org/10.1093/nar/gky318
   PubMed Web of Science ®Google Scholar
• Berman, H. M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T. N., Weissig, H., Shindyalov, I. N., & Bourne, P. E. (2000). The protein data bank. Nucleic Acids Research, 28(1), 235–242. https://doi.org/10.1093/nar/28.1.235
   PubMed Web of Science ®Google Scholar
• Beutner, K. R., & Ferenczy, A. (1997). Reversible hypercapnia in chronic obstructive pulmonary disease: A distinct pattern of respiratory failure with a favorable prognosis. American Journal of Medicine, 102, 28–37.
   PubMed Web of Science ®Google Scholar
• Cherry, J. J., Rietz, A., Malinkevich, A., Liu, Y., Xie, M., Bartolowits, M., Davisson, V. J., Baleja, J. D., & Androphy, E. J. (2013). Structure based identification and characterization of flavonoids that disrupt human papillomavirus-16 E6 function. PloS One, 8(12), e84506. https://doi.org/10.1371/journal.pone.0084506
   PubMed Web of Science ®Google Scholar
• DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2016). Innovation in the pharmaceutical industry: New estimates of R&D costs. Journal of Health Economics, 47, 20–33. https://doi.org/10.1016/j.jhealeco.2016.01.012
   PubMed Web of Science ®Google Scholar
• Friesner, R. A., Banks, J. L., Murphy, R. B., Halgren, T. A., Klicic, J. J., Mainz, D. T., Repasky, M. P., Knoll, E. H., Shelley, M., Perry, J. K., Shaw, D. E., Francis, P., & Shenkin, P. S. (2004). Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. Journal of Medicinal Chemistry, 47(7), 1739–1749. https://doi.org/10.1021/jm0306430
   PubMed Web of Science ®Google Scholar
• Hampson, L., Martin-Hirsch, P., & Hampson, I. N. (2015). An overview of early investigational drugs for the treatment of human papilloma virus infection and associated dysplasia. Expert Opinion on Investigational Drugs, 24(12), 1529–1537. https://doi.org/10.1517/13543784.2015.1099628
   PubMed Web of Science ®Google Scholar
• Howie, H. L., Katzenellenbogen, R. A., & Galloway, D. A. (2009). Papillomavirus E6 proteins. Virology, 384(2), 324–334. https://doi.org/10.1016/j.virol.2008.11.017
   PubMed Web of Science ®Google Scholar
• Irwin, J. J., & Shoichet, B. K. (2005). ZINC–a free database of commercially available compounds for virtual screening. Journal of Chemical Information and Modeling, 45(1), 177–182. https://doi.org/10.1021/ci049714+
   PubMed Web of Science ®Google Scholar
• Kaarthigeyan, K. (2012). Cervical cancer in India and HPV vaccination. Indian Journal of Medical and Paediatric Oncology: Official Journal of Indian Society of Medical & Paediatric Oncology, 33(1), 7–12. https://doi.org/10.4103/0971-5851.96961
   PubMedGoogle Scholar
• Liu, Y., Liu, Z., Androphy, E., Chen, J., & Baleja, J. D. (2004). Design and characterization of helical peptides that inhibit the E6 protein of papillomavirus. Biochemistry, 43(23), 7421–7431. https://doi.org/10.1021/bi049552a
   PubMed Web of Science ®Google Scholar
• Malecka, K. A., Fera, D., Schultz, D. C., Hodawadekar, S., Reichman, M., Donover, P. S., Murphy, M. E., & Marmorstein, R. (2014). Identification and characterization of small molecule human papillomavirus E6 inhibitors. ACS Chemical Biology, 9(7), 1603–1612. https://doi.org/10.1021/cb500229d
   PubMed Web of Science ®Google Scholar
• Martinez-Zapien, D., Ruiz, J., Poirson, F. X., Mitschler, A., Ramirez, J., Forster, A., Cousido-Siah, A., Masson, M., Vande, P. S., Podjarny, A., Travé, G., & Zanier, K. (2016). Structure of the E6/E6AP/p53 complex required for HPV-mediated degradation of p53. Nature, 529(7587), 541–545. https://doi.org/10.1038/nature16481
   PubMed Web of Science ®Google Scholar
• McLaughlin-Drubin, M. E., & Münger, K. (2009). The human papillomavirus E7 oncoprotein. Virology, 384(2), 335–344. https://doi.org/10.1016/j.virol.2008.10.006
   PubMed Web of Science ®Google Scholar
• Mittal, S., & Banks, L. (2017). Molecular mechanisms underlying human papillomavirus E6 and E7 oncoprotein-induced cell transformation. Mutation Research Reviews in Mutation Research, 772, 23–35. https://doi.org/10.1016/j.mrrev.2016.08.001
   PubMed Web of Science ®Google Scholar
• Monie, A., Hung, C. F., Roden, R., & Wu, T. C. (2008). Cervarix™: A vaccine for the prevention of HPV 16, 18-associated cervical cancer. Biologics: Targets & Therapy, 2, 97–105.
   PubMedGoogle Scholar
• Murgueitio, M. S., Bermudez, M., Mortier, J., & Wolber, G. (2012). In silico virtual screening approaches for anti-viral drug discovery. Drug Discovery Today: Technologies, 9(3), 219–225.
   PubMedGoogle Scholar
• Oostenbrink, C., Villa, A., Mark, A. E., & van Gunsteren, W. F. (2004). A biomolecular force field based on the free enthalpy of hydration and solvation: The GROMOS force-field parameter sets 53A5 and 53A6. Journal of Computational Chemistry, 25(13), 1656–1676. https://doi.org/10.1002/jcc.20090
   PubMed Web of Science ®Google Scholar
• Pierce, A. C., Rao, G., & Bemis, G. W. (2004). BREED: Generating novel inhibitors through hybridization of known ligands. Application to CDK2, p38, and HIV protease. Journal of Medicinal Chemistry, 47(11), 2768–2775. https://doi.org/10.1021/jm030543u
   PubMed Web of Science ®Google Scholar
• Rajpoot, S., Alagumuthu, M., & Baig, M. S. (2021). Dual targeting of 3CLpro and PLpro of SARS-CoV-2: A novel structure-based design approach to treat COVID-19. Current Research in Structural Biology, 3, 9–18. https://doi.org/10.1016/j.crstbi.2020.12.001
   PubMedGoogle Scholar
• Scheffner, M., Munger, K., Byrne, J. C., & Howley, P. M. (1991). The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines. Proceedings of the National Academy of Sciences of the United States of America, 88(13), 5523–5527. https://doi.org/10.1073/pnas.88.13.5523
   PubMed Web of Science ®Google Scholar
• Shi, L., Sings, H. L., Bryan, J. T., Wang, B., Wang, Y., Mach, H., Kosinski, M., Washabaugh, M. W., Sitrin, R., & Barr, E. (2007). GARDASIL: Prophylactic human papillomavirus vaccine development–from bench top to bed-side. Clinical Pharmacology and Therapeutics, 81(2), 259–264. https://doi.org/10.1038/sj.clpt.6100055
   PubMed Web of Science ®Google Scholar
• Tungteakkhun, S. S., & Duerksen-Hughes, P. J. (2008). Cellular binding partners of the human papillomavirus E6 protein. Archives of Virology, 153(3), 397–408. https://doi.org/10.1007/s00705-007-0022-5
   PubMed Web of Science ®Google Scholar
• Zanier, K., Charbonnier, S., Sidi, A., McEwen, A. G., Ferrario, M. G., Poussin-Courmontagne, P., Cura, V., Brimer, N., Babah, K. O., Ansari, T., Muller, I., Stote, R. H., Cavarelli, J., Pol, S. V., & Travé, G. (2013). Structural basis for hijacking of cellular LxxLL motifs by papillomavirus E6 oncoproteins. Science (New York, N.Y.), 339(6120), 694–698. https://doi.org/10.1126/science.1229934
   PubMed Web of Science ®Google Scholar
• Zanier, K., Stutz, C., Kintscher, S., Reinz, E., Sehr, P., Bulkescher, J., Hoppe-Seyler, K., Travé, G., & Hoppe-Seyler, F. (2014). The E6AP binding pocket of the HPV16 E6 oncoprotein provides a docking site for a small inhibitory peptide unrelated to E6AP, indicating druggability of E6. PloS One, 9(11), e112514. https://doi.org/10.1371/journal.pone.0112514
   PubMed Web of Science ®Google Scholar